LGM
ARQT icon

Logos Global Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Logos Global Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,400,000
Closed -$20.7M – 45
2022
Q4 		$20.7M Sell
1,400,000
-125,000
-8% -$2.18M 2.43% 18
2022
Q3 		$29.1M Buy
1,525,000
+525,000
+53% +$11.9M 3.58% 10
2022
Q2 		$21.3M Sell
1,000,000
-500,000
-33% -$10.3M 3.91% 11
2022
Q1 		$28.9M Buy
1,500,000
+1,250,000
+500% +$21.1M 3.75% 12
2021
Q4 		$5.18M Buy
+250,000
New +$4.98M 0.53% 40

Other funds holding ARQT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Logos Global Management's ARQT Position: Q1 2023 in Review

Logos Global Management sold out of Arcutis Biotherapeutics (ARQT) in Q1 2023, closing a stake of 1,400,000 shares — an estimated $20.7M sold.

Logos Global Management first reported a position in ARQT in Q4 2021 and held it in 5 quarters. The position peaked at $29.1M in Q3 2022. 143 funds tracked by Wall St. Rank hold ARQT as of Q1 2023.

  • Logos Global Management reported no remaining Arcutis Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Logos Global Management sold 1,400,000 Arcutis Biotherapeutics shares in Q1 2023, an estimated $20.7M.
  • Logos Global Management first reported a position in Arcutis Biotherapeutics in Q4 2021 and held it in 5 quarters.
  • Logos Global Management's Arcutis Biotherapeutics position peaked at $29.1M in Q3 2022.
  • 143 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2023.

Based on Logos Global Management's 13F filing for Q1 2023, filed 15 May 2023.